Core Laboratories (CLB) Misses Q3 EPS by 3c, provides guidance

Core Laboratories (NYSE: CLB) reported Q3 EPS of $0.25, $0.03 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $134.4 million versus the consensus estimate of $139.66 million.

GUIDANCE:

Core Laboratories sees Q4 2024 EPS of $0.20-$0.25, versus the consensus of $0.24. Core Laboratories sees Q4 2024 revenue of $128.5-135.5 million, versus the consensus of $134 million.

For earnings history and earnings-related data on Core Laboratories (CLB) click here.

You May Also Be Interested In

• GameStop CEO Cohen buys 1.15M shares
• Iambic Therapeutics (IAM) files for proposed IPO
• Boeing wins defense contracts worth $41.5m for aircraft support